Side-by-Side Comparison
Melanotan II vs PT-141: Mechanism, Evidence & Safety Compared
An evidence-based side-by-side look at how Melanotan II and PT-141 differ in mechanism, regulatory status, strength of the research base, and clinical application — compiled from the published literature and the FDA regulatory record.
Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.
Also: MT-2, MT-II
A melanocortin receptor agonist that stimulates melanin production (tanning) and has sexual function effects. Significant safety concerns.
PT-141
L5Also: Bremelanotide, Vyleesi
An FDA-approved melanocortin receptor agonist used for hypoactive sexual desire disorder in premenopausal women.
Side-by-side comparison
| Attribute | Melanotan II | PT-141 |
|---|---|---|
| Primary mechanism | Non-Selective Melanocortin Agonism | Melanocortin MC4R Agonism |
| FDA status | Research Only | FDA Approved |
| Evidence level | Emerging Clinical Evidence | FDA Approved |
| Human trials | Yes (6+ indexed) | Yes (10+ indexed) |
| Studies indexed | 59 total (6 human, 35 animal) | 56 total (18 human, 25 animal) |
| Primary uses researched | Skin tanning, Erectile dysfunction (research), Sun protection (research) | Female sexual desire, Erectile dysfunction (off-label research) |
| Administration routes | subcutaneous | subcutaneous |
| Molecular weight | 1024.18 Da | 1025.18 Da |
| Amino acids | 7 | 7 |
| Category | skin hair | sexual health |
| WADA status | Permitted | Permitted |
Key differences
Mechanism. Both compounds share the same primary mechanism (non-selective melanocortin agonism), so differences between them are driven by pharmacokinetics, selectivity, and clinical data rather than mechanism class.
Regulatory status. Melanotan II is classified as research only; PT-141 is classified as fda approved. Regulatory status drives availability, legality, and the standard of evidence required for specific therapeutic claims.
Evidence base. PT-141 sits at a higher evidence level (L5) than Melanotan II (L3) under PeptideMark's L1–L5 methodology.
Research focus. Published research on Melanotan II has concentrated on skin tanning, erectile dysfunction (research), sun protection (research). Research on PT-141 has concentrated on female sexual desire, erectile dysfunction (off-label research). These research programs have limited overlap, and comparisons are most useful when readers are evaluating adjacent therapeutic goals.
Safety snapshot
| Attribute | Melanotan II | PT-141 |
|---|---|---|
| Documented effects | 11 total | 8 total |
| Serious events | 1 | 0 |
| Common events | 7 | 4 |
| Black box warning | No | No |
| Contraindications | 5 listed | 3 listed |
| Drug interactions | 2 flagged | 2 flagged |
| Most common event | Nausea | Nausea |
Strengths & limitations
Melanotan II
Strengths
- Multiple human clinical trials (6+ indexed)
- Not on the WADA prohibited list
Limitations
- Not FDA-approved for any indication — research use only
PT-141
Strengths
- FDA-approved with established regulatory record
- Strong evidence base (L5)
- Multiple human clinical trials (10+ indexed)
- Not on the WADA prohibited list
Limitations
- Direct head-to-head comparison data against peers is limited
Representative studies
Melanotan II
Melanocortin-based therapeutics for erection and libido dysfunction
Hadley ME, et al. · International Journal of Impotence Research (2006)
Melanotan II demonstrated both skin tanning and pro-erectile effects in human studies, leading to development of PT-141.
PubMed 16107869Melanotan II increases tanning response and suppresses appetite in fair-skinned volunteers
Haskell-Luevano C, Sawyer TK, Hendrata S, et al. · Clinical & Experimental Dermatology (1998)
Melanotan II induced 3-4 Fitzpatrick shade darkening; appetite suppression occurred (hunger scores reduced 27%), separate from tanning effect.
PubMed 9876138PT-141
Bremelanotide for Female Sexual Dysfunctions in Premenopausal Women: A Randomized, Placebo-Controlled Dose-Finding Trial
Clayton AH, Althof SE, Kingsberg S, et al. · Womens Health (2016)
Bremelanotide 1.75mg significantly improved sexual desire scores and reduced sexually related distress, establishing the dose for Phase 3.
PubMed 27216973Bremelanotide for Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial (RECONNECT)
Kingsberg SA, Clayton AH, Portman D, et al. · Obstetrics & Gynecology (2019)
Bremelanotide met both co-primary endpoints in the pivotal trials, leading to FDA approval as Vyleesi — the first on-demand treatment for female HSDD.
PubMed 31599840Frequently asked
What is the main difference between Melanotan II and PT-141?
Melanotan II is a melanocortin receptor agonist that stimulates melanin production (tanning) and has sexual function effects. significant safety concerns. Its primary mechanism is non-selective melanocortin agonism. PT-141 is an fda-approved melanocortin receptor agonist used for hypoactive sexual desire disorder in premenopausal women. Its primary mechanism is melanocortin mc4r agonism. The two differ in regulatory status (Research Only vs FDA Approved), strength of evidence (L3 vs L5), and the primary conditions for which each is researched.
Is Melanotan II or PT-141 FDA approved?
Melanotan II: Not FDA-approved. Sold illegally as a tanning product. FDA has issued multiple warnings about unlicensed products. PT-141: FDA-approved in 2019 as Vyleesi for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.
How does the evidence base compare?
Melanotan II has 59 indexed studies (6 human, 35 animal) and is rated Emerging Clinical Evidence. PT-141 has 56 indexed studies (18 human, 25 animal) and is rated FDA Approved. Evidence ratings reflect PeptideMark's L1–L5 methodology based on study type, sample size, and replication.
Can Melanotan II and PT-141 be compared directly?
Melanotan II and PT-141 come from different therapeutic categories (skin hair vs sexual health), so direct clinical comparison is limited. Readers often compare them because of overlapping research interest, shared patient populations, or adjacent mechanisms — not because head-to-head trial data exists.
Are Melanotan II and PT-141 commonly stacked together?
There is no widely documented stacking protocol combining Melanotan II and PT-141 in the peer-reviewed literature. Any combination use should be supervised by a qualified clinician familiar with both compounds' pharmacology and contraindications.
Which has a better-documented safety profile, Melanotan II or PT-141?
Melanotan II has 11 documented side effects (1 serious). PT-141 has 8 documented side effects (0 serious). Better documentation does not necessarily mean safer — FDA-approved drugs have more rigorous adverse-event reporting, while research-only compounds may appear "cleaner" simply because fewer controlled trials have captured events systematically.
How are Melanotan II and PT-141 administered?
Both are administered via subcutaneous. Practical dosing differences come down to frequency, concentration, and titration schedule rather than route of administration.
Which is better, Melanotan II or PT-141?
"Better" depends on the therapeutic goal, regulatory context, and individual response. Melanotan II is most researched for skin tanning and erectile dysfunction (research); PT-141 is most researched for female sexual desire and erectile dysfunction (off-label research). FDA status also matters: Research Only for Melanotan II vs FDA Approved for PT-141. This page is educational — any decision to use either compound should be made with a qualified clinician who has reviewed your medical history.
Full profile
Melanotan II →
Full profile
PT-141 →